Intercept Pharmaceuticals Stock News

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madrigal Pharmaceuticals' resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.

U.S. stocks traded lower, with the Dow Jones dropping over 300 points on Wednesday. Here are some big stocks recording gains in today’s session. eHealth, Inc. (NASDAQ: EHTH) shares jumped 26.9% to

Due to what is seemingly a successful comeback, you can expect Intercept Pharmaceuticals to potentially deliver several-fold returns. Ocaliva's revenue for PBC alone is nearly enough to bank a net pro

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the posi

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.

Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.

Gainers Expion360 Inc. (NASDAQ: XPON) shares jumped 175% to $2.70 after the company announced it has been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trail

NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study

Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. Axcella H